Open AccessExploring a ‘pro-senescence’ approach for prostate cancer therapy by targeting PTEN
Author(s) -
Manuel Collado
Publication year - 2010
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon.10.39
Subject(s) - senescence , pten , prostate cancer , carcinogenesis , cancer research , medicine , cancer , suppressor , cellular senescence , prostate , oncology , biology , signal transduction , pi3k/akt/mtor pathway , microbiology and biotechnology , phenotype , genetics , gene
Evaluation of: Alimonti A, Nardella C, Chen Z et al.: A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 120(3), 681–693 (2010). Cellular senescence has proven its power in controlling tumor growth in various mouse models of cancer, and there are some hints pointing to its relevance in cancer chemotherapy. This article characterizes the induction of cellular senescence after decreasing the levels of tumor suppressor PTEN, and further investigates the potential therapeutic benefit of targeting cellular senescence induction for cancer therapy.